Probiotics And Ulcerative colitis

A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis.

Fujimori, S., Gudis, K., Mitsui, K., Seo, T., Yonezawa, M., Tanaka, S., Tatsuguchi, A., and Sakamoto, C.

Nutrition – 01-MAY-2009; 25(5): 520-5

Objectives: To compare the use of probiotics, prebiotics or combined (synbiotic) therapy in the treatment of ulcerative colitis (UC)

Methods: 120 UC out-patients were randomly assigned to one of 3 groups (N=40 each). The probiotic group were given one daily capsule containing Bifidobacterium longum (2 x 109CFU). The prebiotic group was given a daily dose of 8.0g of psyllium (prebiotic). The synbiotic group received both the B. longum and the psyllium at the same dosage. All patients completed a quality-of-life questionnaire at 2 weeks and again at 4 weeks. The questionnaire was scored and results compared. C-reactive protein, CRP, as a measure of inflammation was also tested.

Results: All groups showed an improvement in their questionnaire scores at 4 weeks, with the synbiotic group showing the greatest improvement (p=0.03) in quality-of-life scoring. CRP levels decreased significantly only with the synbiotic group. (p=0.04)

Conclusions: Synbiotic therapy of UC patients shows promise in improving the quality of life and appears to have synergistic activity in improving inflammatory parameters, as measured by CRP as well.